BioSpace News Archive

Nanalysis Scientific Corp. announces that on Wednesday, May 29th, 2024, the Company will put out a press release and Chief Executive Officer Sean Krakiwsky and Chief Financial Officer Randall McRae will host a conference call at 5:00 P.M. Eastern Time to discuss the results for the quarter ending March 31, 2024.

IceCure Medical Ltd. announced today that it will issue a press release containing its financial and operational results as of and for the three months ended March 31, 2024 before the Nasdaq Stock Market opens on Tuesday, May 28, 2024.

Cingulate Inc. announced that it has received confirmation from and is aligned with the U.S. Food and Drug Administration (FDA) on the requirements necessary for filing a New Drug Application (NDA) for its lead Phase 3 candidate CTx-1301 (dexmethylphenidate), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients six years of age or older.

Alzheimer’s Community Care will host its 25th Annual Education Conference on Wednesday, May 22nd at the Marriott Palm Beach Gardens from 8-4 p.m.

Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), today announced that it is advancing its goal to preserve capital by implementing a layoff of approximately 75% of its workforce, in addition to other cost-cutting measures.

PharmaCyte Biotech, Inc. today announced a $7 million investment in MyMD Pharmaceuticals, Inc.

Intrommune Therapeutics, Inc. is pleased to announce its participation in three renowned industry events during May.

Brainomix, a pioneer in artificial intelligence (AI) imaging solutions to enable precision medicine, is proud to announce the FDA clearance of its latest product

Brainomix, a pioneer in artificial intelligence (AI) imaging solutions to enable precision medicine, announced a series of new studies that were presented this week at the European Stroke Organisation Conference

iLeadBMS, a leading biotech company dedicated to the discovery and development of novel drugs for high unmet medical needs, has announced a positive outcome of IL1512, a first-in-class CXCR7 agonist, as a potential therapy for pulmonary fibrotic diseases